LCM Capital Management Inc Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

LCM Capital Management Inc increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,963 shares of the medical research company’s stock after purchasing an additional 50 shares during the quarter. Thermo Fisher Scientific accounts for about 0.7% of LCM Capital Management Inc’s investment portfolio, making the stock its 29th largest holding. LCM Capital Management Inc’s holdings in Thermo Fisher Scientific were worth $1,214,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. BDF Gestion acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $6,368,000. Nisa Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company’s stock valued at $87,093,000 after purchasing an additional 8,180 shares during the period. Lord Abbett & CO. LLC boosted its stake in shares of Thermo Fisher Scientific by 1.9% in the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock valued at $45,478,000 after purchasing an additional 1,480 shares during the period. Advisors Capital Management LLC increased its stake in Thermo Fisher Scientific by 5.8% during the 1st quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock worth $64,613,000 after buying an additional 6,089 shares during the period. Finally, Seven Eight Capital LP acquired a new position in Thermo Fisher Scientific in the 1st quarter worth $1,161,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.7 %

Shares of NYSE:TMO opened at $546.55 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $433.15 and a fifty-two week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $208.78 billion, a PE ratio of 34.27, a P/E/G ratio of 3.64 and a beta of 0.77. The company’s 50-day moving average price is $600.36 and its 200 day moving average price is $583.31.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.69 earnings per share. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,300 shares of company stock valued at $6,831,268 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMO. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Stephens started coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Finally, Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.